Plasma miR-323 as a Biomarker for Screening Papillary Thyroid Cancer From Healthy Controls

Yang Liu††, Lin Li††, Zheng Liu†, Qingling Yuan† and Xiubo Lu*†

† Department of Thyroid Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, ‡ Department of Dermatology, Henan Children's Hospital, Zhengzhou, China

The present study aims to evaluate whether plasma miR-323 serves as a potential biomarker to screen patients with papillary thyroid cancer (PTC) from healthy controls. Real-time PCR was performed to evaluate miR-323 expression in healthy controls and benign thyroid nodule (BTN) and PTC patients. Receiver operating characteristic (ROC) curve analysis was used to evaluate whether plasma miR-323 could be used to screen PTC patients from BTN patients and healthy controls. Plasma miR-323 was significantly increased in PTC patients compared with that in BTN patients and healthy controls. Moreover, miR-323 in the thyroid tissue was significantly increased in PTC patients when compared to BTN patients. We further showed that plasma and tissue miR-323 levels were significantly increased in PTC patients with metastasis compared to those without metastasis. Plasma miR-323 was significantly increased in PTC patients with BRAF V600E mutation when compared to those with wild-type BRAF. Furthermore, plasma miR-323 was significantly increased in PTC patients with higher Tg-FNAB. ROC analysis showed that plasma miR-323 could distinguish PTC patients from BTN patients and healthy controls. The present study demonstrated that plasma miR-323 might be an effective noninvasive indicator for PTC progression and serve as a biomarker for the diagnosis of PTC.

Keywords: plasma miR-323, papillary thyroid cancer, metastasis, biomarker, fine-needle aspiration cytology

INTRODUCTION

Thyroid cancer is the most common malignant endocrine tumor, and its prevalence is rapidly increasing worldwide (1). Approximately 300,000 new patients are diagnosed each year, with around 40,000 deaths per year (1, 2). Papillary thyroid cancer (PTC), a differentiated neoplasia, is the most prevalent type among all thyroid cancers (3). It is of clinical importance to distinguish PTC from benign thyroid nodules (BTN), including thyroid adenoma and classical nodular goiter. Currently, ultrasound and computed tomography (CT) are routinely used to examine patients with suspicious thyroid nodules (4), after which preoperative ultrasound-guided fine-needle aspiration cytology (FNAC) and intraoperative pathological examination are subsequently employed to examine the patients with suspicious PTC (4). FNAC serves as an efficient, cost-effective, and reliable diagnostic tool with remarkable sensitivity and relative low specificity for the initial screening of patients with thyroid nodules (5). As an invasive approach with potential false negative and false positive, the diagnostic efficacy and accuracy of FNAC in PTC patients were compromised with various influencing factors such as the thyroid nodule size (6) and the misinterpretation of...
cytopathological results due to the morphological overlap between PTC in chronic lymphocytic thyroiditis and pure thyroditis (7, 8). Nonetheless, these observations necessitate the development and validation of novel non-invasive approaches to improve the disease detection in early stage and prediction of disease prognosis in PTC patients (9). Recently preoperative molecular analysis using a panel of genetic alterations emerges as a new approach to make up the limitation of FNA diagnosis (10). Therefore, it is of clinical importance to explore noninvasive biomarkers to screen patients from individuals with benign thyroid lesions.

MicroRNAs are small noncoding RNAs with approximately 22 nucleotides (11). Through base pairing mechanism, miRNAs are extensively involved in the regulation of various biological and pathological processes, including cell proliferation, differentiation, and death (12–14). Currently, accumulating studies have identified various miRNAs as ideal biomarkers since they stably present in the serum and plasma and can be detected with high sensitivity and specificity (15, 16). For instance, miR-126-3p serves as a tumor suppressor to inhibit thyroid cancer cell growth and metastasis (17). miR-375 suppresses thyroid carcinoma cell proliferation and induce cell apoptosis via binding the 3’ untranslated region of ERBB2 (18). Meanwhile, miR-222 and miR-146b are positively correlated with the progression of PTC in the tissue and serum of patients with recurrent PTC (19). It was recently reported that miR-323 was dysregulated in prostate cancer and pancreatic ductal adenocarcinoma (19, 20), while little is known about its role in the progression of PTC. The current study aimed to evaluate the correlation of miR-323 with PTC progression and its potential role as a biomarker to screen patients with PTC from healthy controls.

MATERIALS AND METHODS

Patients

This study protocol was approved by the Medical Institutional Ethics Committee of the First Affiliated Hospital of Zhengzhou University. A total of 100 patients with primary PTC, 50 patients with BTNs, and 20 age- and gender-matched healthy controls from the First Affiliated Hospital of Zhengzhou University were enrolled in this study from March 2015 to December 2016. Written informed consent was obtained from all participants. The formalin-fixed and paraffin-embedded (FFPE) PTC tissues or BTN tissues were used for the postoperative histopathologic diagnosis and miRNA examination. The freshly isolated samples were immediately frozen for preparing total RNA. In addition, blood samples were isolated from all subjects before surgery and were also collected from six patients after tumor resection and radiometabolic therapy for 2 weeks after surgery. The details of the clinical features are shown in Table 1.

US-Guided Fine Needle Aspiration Biopsy (FNAB) Cytology of Thyroid Nodules

FNAB was carried out by endocrinologists using a 25-gauge needle. After each pass, the cytological material was immediately smeared onto slides. The slides were prepared by both air-dried and alcohol-fixed methods. The air-dried smears were stained with the Diff-Quik method for an immediate on-site evaluation, whereas the alcohol-fixed smears were stained with the Papanicolaou method in the cytological laboratory.

A cytopathologist performed an on-site evaluation after each FNA pass. Thereafter, the material from the Diff-Quik smears was deemed arbitrarily as “adequate” (sufficient lymphocytes), “less than optimal” (some lymphocytes), or “inadequate” (very few or no lymphocytes); a dedicated FNA pass was performed without smears, and the FNA needle was rinsed in a tube containing 1 ml of Hank’s balanced salt solution without heparin. Specimens were immediately transferred to the clinical laboratory and stored at −20°C for 0 to 4 days before thyroglobulin (Tg) analysis. For each case, all passes were performed by the same endocrinologist.

Tg-FNAB Antibody Assays

The measurement of Tg levels in needle washouts (Tg-FNAB) was carried out with a commercial immunofluorometric assay using monoclonal antibodies (DELFIA®, PerkinElmer, Turku, Finland), with a functional sensitivity of 1.0 ng/ml.

Sample Acquisition and RNA Extraction

Plasma miR-323 was evaluated at first diagnosis, prior to any treatment, in all involved participants, unless specified (e.g., follow-up study). A 5-ml aliquot of blood was collected from each participant directly into sodium citrate tubes. Ten micromolars of freshly isolated samples with remarkable lesions from PTC or BTN patients were processed in lysis buffer at 4°C and proceeded to further miRNA analysis. Total RNA from plasma samples and freshly isolated tissue samples was extracted with RNAzol LS (Vigorous, Beijing, China) according to the specific instructions for small RNA isolation. The quality, quantity, and integrity of RNA were determined using a NanoDrop spectrophotometer (ND-1000, Nanodrop Technologies).

| Variable | PTC patients | BTN patients | Healthy controls |
|----------|--------------|--------------|-----------------|
| Male/female | 53/47 | 22/28 | 9/11 |
| Age (year) | 54.3 ± 10.3 | 48.9 ± 15.1 | 55.7 ± 8.7 |
| Tumor size (cm) | ≤1 | 56 | – | – |
| | >1 | 44 | – | – |
| Capsular invasion | Yes | 32 | – | – |
| | No | 68 | – | – |
| Lymph node metastasis | Yes | 35 | – | – |
| | No | 65 | – | – |
| No. of cancer foci | Single | 56 | – | – |
| | Multiple | 44 | – | – |
| BRAFV600E gene | Mutant | 72 | – | – |
| | Wide type | 28 | – | – |
RNA was reverse transcribed into cDNA with the Prime-Script one-step qRT-PCR kit (C28025-032, Invitrogen). Detailed qRT-PCR procedure was performed as follows: 95°C for 10 min followed by 50 cycles at 95°C for 10 s, 55°C for 10 s, and 72°C for 5 s; 99°C for 1 s; 59°C for 15 s; 95°C for 1 s; and then cooling to 40°C. The relative expression levels were calculated with the $2^{-\Delta\Delta Ct}$ method and experiments were repeated in triplicate. The specific primers used in the current study were listed as follows:

- miR-323-RT: GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGAGCGAA;
- U6-RT: GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACAAATATG;
- miR-323-F: GCGCAGGTGGTCCGTGGCGCG;
- U6-F: GCGCGTCGTGAAGCGTTC;
- Universe reverse primer: GTGCAGGGTCCGAGGT.

**BRAFV600E Gene Testing**

The determination of BRAFV600E gene mutation was carried out for all PTC patients by PCR techniques. DNA was isolated using a DNA extraction kit (Promega Corporation, CA, USA), and the BRAF gene exon 15 was detected using a BRAF mutant gene detection kit (Amoy Diagnostics Co., LTD, China) on an ABI7500 real-time PCR amplifier (Promega Corporation, CA, USA). The primers used for the amplification of BRAF exon 15 were presented as follows: forward (5′-TCATAATGCTTGCTCTGATAGGA-3′) and reverse (5′-GGCCAAAATTTAATCAGTGGA-3′). All procedures and analyses were performed in the institutional biomolecular laboratory.

**Statistics**

The data are represented as mean ± standard error (SD). Two-tailed unpaired Student's t-tests were used for comparisons of two groups. ANOVA multiple comparison test (SPSS 13.0) followed by Tukey's post hoc test were used for comparisons of two and more groups. Receiver operating characteristic (ROC) curves were used to assess miR-323 as a biomarker, and the area under the curve (AUC) was reported (version 20.0, SPSS, Inc., Chicago, Illinois). $p < 0.05$ was considered significant.

**RESULTS**

**Increased Plasma miR-323 Level in PTC Patients**

First, we evaluated the level of miR-323 in PTC patients, BTN patients, and healthy controls. Compared with the results for healthy controls, the plasma level of miR-323 was significantly increased in PTC patients, but not in BTN patients (Figure 1A). Furthermore, we also compared the plasma level of miR-323 in nonmetastatic and metastatic patients with PTC. Our data showed that miR-323 was significantly increased in metastatic PTC patients when compared to nonmetastatic PTC patients (Figure 1B).

**miR-323 Was Increased in the Tissues of PTC Patients**

Next, we isolated RNA from tissues of PTC patients and BTN patients. Real-time PCR analysis indicated that miR-323 was significantly increased in the tissues of PTC patients when compared with those in BTN patients (Figure 1C). Meanwhile, our data also showed that miR-323 was increased in the tissues of metastatic PTC patients when compared to those of nonmetastatic PTC patients (Figure 1D).

**miR-323 Was Increased in the Plasma and Tissues of BRAFV600E Mutant PTC Patients**

Compared with wild-type BRAFV600E PTC patients, plasma miR-323 was significantly increased in the plasma of BRAFV600E mutant PTC patients (Figure 2A). We further compared the levels of miR-323 in the tissues of BRAFV600E wild-type PTC patients and BRAFV600E mutant PTC patients. Our data showed that miR-323 was significantly increased in the thyroid tissues of BRAFV600E mutant PTC patients.
BRAF<sup>V600E</sup> mutant PTC patients compared to those of wild-type PTC patients (Figure 2B). We also found the increased plasma miR-323 level in PTC patients with wild-type BRAF<sup>V600E</sup> when compared to healthy controls (Figure 2C).

**miR-323 Levels Positively Correlated With Tg-FNAB Levels**

The measurement of Tg in needle washouts (Tg-FNAB) is an important confirmation of malignancy in lymph nodes (LNs). Hence, we compared the level of plasma miR-323 among the groups of differential concentration of Tg-FNAB. As shown in Figure 4, the level of plasma miR-323 was lower in PTC patients with Tg-FNAB ≤1 ng/ml, while it was significantly increased in PTC patients with Tg-FNAB >1 ng/ml. We further found that plasma miR-323 in PTC patients with Tg-FNAB >10 ng/ml was significantly higher in those patients with 1 ng/ml < Tg-FNAB ≤10 ng/ml (Figure 3).

**Plasma miR-323 Was Decreased in PTC Patients After Surgery and Appropriate Therapy**

We also carried out a follow-up assay for six PTC patients after they received appropriate treatment for 2 weeks. After surgery and two-week therapy, the relative plasma level of miR-323 was significantly decreased in the six PTC patients (p < 0.01, Figure 4).

**miR-323 Could Be Used to Screen PTC Patients From Healthy Controls**

We evaluated whether miR-323 could be used as a potential biomarker to screen PTC patients from healthy controls. As shown in Figure 5A, while plasma miR-323 failed to distinguish BNT patients from healthy controls, as shown by the ROC curve area of 0.515 (95% confidence interval: 0.349–0.681; p = 0.857, Figure 5A), it could distinguish PTC patients from healthy controls, as shown by the ROC curve area of 0.942 (95% confidence interval: 0.858–1.000; p < 0.001, Figure 5B). Meanwhile, plasma miR-323 could also distinguish...
BNT patients from PTC patients, as shown by the ROC curve area of 0.912 (95% confidence interval: 0.819–1.000; p < 0.001, Figure 5C). In addition, plasma miR-323 was shown to distinguish nonmetastatic PTC patients from metastatic PTC patients, as shown by the ROC curve area of 0.831 (95% confidence interval: 0.688–0.973; p < 0.001, Figure 5D). These data suggested that plasma miR-323 levels could serve as a potential biomarker to screen PTC patients from healthy controls and BNT patients.

**DISCUSSION**

Currently, it is important to identify potential molecular predictors of PTC patients (21, 22). BRAF mutation is indicated as a potential marker of aggressive PTC, but it mainly depends on invasive fine-needle aspiration diagnosis (23). In addition, p27, p21, cyclin D1, CEACAM-1 (carcinoembryonic antigen-related cell adhesion molecule 1), osteopontin, and E-cadherin are also reported as potential biomarkers (24, 25), which are still far from clinical applications. The present study demonstrated that miR-323 was significantly increased in the plasma and thyroid tissue in PTC patients, and its expression was correlated with metastasis, BRAFV600E mutant, Tg-FNAB, and appropriate therapy. It can serve as a potential biomarker to distinguish PTC patients from BNT patients and healthy controls.

Abnormal expression of miRNAs has been widely identified in both papillary and follicular thyroid cancer (PTC) tissues (26–28). For instance, miR-144-3p is reported to increase the growth of tumor and the metastasis of PTC via suppressing the expression of PAX 8, which may be a promising prognosis marker and valuable treatment strategy for PTC (26). In addition, reduced miR-199a-5p expression is found in PTC tissues, and further study demonstrated that SNAI1 was a target gene of miR-199a-5p (27). The rs2910164 genetic variant of miR-146a-3p is also reported to be correlated with enhanced overall mortality in FTC patients (28). Additionally, miR-323 was significantly increased in patients with hereditary MTC (hMTC) and sporadic MTC (sMTC) (29). A previous *in vitro* study reported a decreased miR-323 in PTC cell line with BRAF mutations when compared to normal thyroid cell line (30). In the current study, we evaluated the level of plasma miR-323 in healthy controls, BNT patients, and PTC patients. We confirmed that plasma miR-323 of PTC patients was significantly increased compared with that of BNT patients and healthy controls. Meanwhile, thyroid tissue levels of miR-323 were strongly increased in PTC patients compared to BNT patients. The above observations suggested an oncogenic role of miR-323 in the progression of PTC.

A high survival rate has been found in patients with well-differentiated thyroid cancer (31). It is well recognized that the progression of metastasis is still the major cause of thyroid cancer-related mortality (32). Hence, it is important to identify genes related to this process, thereby identifying novel candidates for diagnosis or therapeutic intervention (33). Here, our data showed that plasma and tissue miR-323 levels were significantly increased in PTC patients with metastasis when compared to nonmetastatic patients.

The T1799A nucleotide transversion in the *BRAF* gene is an important oncogenic mutation linked to PTC (34, 35). It has been reported that 45% of PTC patients are carrying another mutation characterized by a valine-to-glutamic acid change in codon 600 of the BRAF protein (*BRAF* V600E), which increases the serine/threonine protein kinase activity of BRAF and thereby constitutively activates the mitogen-activated protein kinase signaling pathway (36, 37). Hence, the *BRAF* V600E is a potential key prognostic marker for PTC (36, 37). Our current results showed that plasma miR-323 level was significantly increased in PTC patients with *BRAF* V600E mutation compared to those with wild-type BRAF, while plasma miR-323 level in PTC patients with wild-type *BRAF* V600E was also significantly increased when compared to healthy controls. This likely reflects that elevated plasma miR-323 is potentially associated with the more aggressive clinicopathological behavior of *BRAF* V600E mutation PTC.

In the clinic, the application of Tg-FNAB is well acknowledged as an important method to examine suspicious LN metastases (38, 39). However, 5–10% of FNABs are nondiagnostic, and 6–8% are false negatives (40). Hence, we explored the differential plasma miR-323 levels in PTC patients with different concentrations of Tg-FNAB. Compared with PTC patients with Tg-FNAB ≤1 ng/ml, plasma miR-323 levels were significantly increased in PTC patients with Tg-FNAB >1 ng/ml. This finding suggests that the analysis of plasma miR-323 levels could serve as an implemental invasive diagnostic method in line with Tg-FNAB levels, in which the accuracy of the Tg-FNAB method could increase when combined with analysis of plasma miR-323 levels.

ROC analysis was also employed to further evaluate whether miR-323 could be used as a potential biomarker to screen PTC patients from BNT patients and healthy controls. Our data showed that analysis of plasma miR-323 levels could effectively differentiate PTC patients from BNT patients and healthy controls.

*In silico* analysis with Targetscan software was applied to predict the potential targets of human miR-323, which revealed 488 transcripts with conserved sites as shown in Supplementary Table 1. Actually, multiple proteins and
signaling pathways [e.g., p73 (19), insulin-like growth factor 1 receptor (41), and BRI3 (42)] were previously proposed to mediate the potential role of miR-323 in the pathogenesis and progress of various types of neoplasia. For instance, miR-323-3p suppressed the expression of transmembrane protein with EGF-like and 2 follistatin domain (TMEFF2) and the activation of AKT and ERK pathways, by which it inhibited the apoptosis in non-small-cell lung cancer (NSCLC) cell lines (43).

While the current study demonstrated for the first time that plasma miR-323 may be a validated noninvasive indicator for PTC progression, some limitations exist. For example, the molecular mechanism underlying miR-323 involvement in PTC progression need to be elucidated. Meanwhile, further study with a larger case population is also in need to validate the efficacy of plasma miR-323 and its correlation with serum/tissue Tg as a biomarker to evaluate the tumor progression, prognosis, and recurrence in clinical patients with PTC.

DATA AVAILABILITY STATEMENT

The datasets generated for this study are available on request to the corresponding author.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Medical Institutional Ethics Committee of the First Affiliated Hospital of Zhengzhou University. The
patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

YL and XL designed the study. YL, LL, ZL, and QL collected the data. YL, LL, and XL analyzed the data. YL and XL wrote the manuscript.

REFERENCES

1. Haugen BR, Sawka AM, Alexander EK, Bible KC, Caturegli P, Doherty GM, et al. American thyroid association guidelines on the management of thyroid nodules and differentiated thyroid cancer task force review and recommendation on the proposed renaming of encapsulated follicular variant papillary thyroid carcinoma without invasion to noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Thyroid. (2017) 27:481–3. doi: 10.1089/thy.2016.0628
2. Yao H, Pan C, Chen W, Li T, Zhu W, Qi J. Differentiation between malignant and benign thyroid nodules and stratification of papillary thyroid cancer with aggressive histological features: whole-lesion diffusion-weighted imaging histogram analysis. J Magn Res Imag. (2016) 44:1546–55. doi: 10.1002/jmri.25290
3. Fusco A, Chiappetta G, Hui P, Garcia-Rostan G, Golden L, Kinder BK, et al. Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer. Am J Pathol. (2002) 160:2157–67. doi: 10.1016/S0002-9440(10)61164-9
4. Brace MD, Wang J, Petten M, Bullock MJ, Makki F, Trites J, et al. Differential expression of transforming growth factor-beta in benign vs. papillary thyroid cancer nodules: a potential diagnostic tool? J Otolaryngol. (2014) 43:22. doi: 10.1186/s40463-014-0022-x
5. Zhu Y, Song Y, Xu G, Fan Z, Ren W. Causes of misdiagnoses by thyroid fine-needle aspiration cytology (FNAC): our experience and a systematic review. Diag Pathol. (2020) 15:1. doi: 10.1186/s13000-019-0924-z
6. Aydogan BI, Sahin M, Ceyhan K, Deniz O, Demir O, Emral R, et al. The influence of thyroid nodule size on the diagnostic efficacy and accuracy of ultrasound guided fine-needle aspiration cytology. Diagn Cytopathol. (2019) 47:682–7. doi: 10.1002/dc.24170
7. Faser CR, Marley EE, Oertel YC. Papillary thyroid tissue fragments as a diagnostic pitfall in fine-needle aspirations of thyroid nodules. Diagn Cytopathol. (1997) 16:454–9. doi: 10.1002/(SICI)1097-0339(19970516)16:5<454::AID-DC14>3.0.CO;2-I
8. Yi KI, Ahn S, Park DY, Lee JC, Lee BJ, Wang SG, et al. False-positive cytology results for papillary thyroid carcinoma: a trap for thyroid surgeons. Clin Otolaryngol. (2017) 42:1153–160. doi: 10.1111/coa.12840
9. Abdullah MI, Junit SM, Ng KL, Jayapalan J, Karikalan B, Hashim OH. Papillary thyroid cancer: genetic alterations and molecular biomarker investigations. Int J Med Sci. (2019) 16:450–60. doi: 10.7150/ijms.29935
10. Ko YS, Hwang TS, Kim JY, Choi YL, Lee SE, Han HS, et al. Diagnostic limitation of fine-Needle aspiration (FNA) on indeterminate thyroid nodules can be partially overcome by preoperative molecular analysis: assessment of RET/PTC1 rearrangement in BRAF and RAS wild-Type routine Air-Dried FNA specimens. Int J Mol Sci. (2017) 18:806. doi: 10.3390/ijms18040806
11. Baldini E, Tuccilli C, Prinzi N, Sorrenti S, Falvo L, De Vito C, et al. Deregulated expression of aurora kinases is not a prognostic biomarker in papillary thyroid cancer patients. PLoS ONE. (2015) 10:e0121514. doi: 10.1371/journal.pone.0121514
12. Komatsu S, Ichikawa D, Takeshita H, Morimura R, Hiraijima S, Tsujiura M, et al. Circulating miR-18a: a sensitive cancer screening biomarker in human cancer. In vivo. (2014) 28:293–7.
13. Kirahashi J, Mima K, Sawada G, Takahashi Y, Eguchi H, Sugimachi K, et al. Epigenetic modulation and repression of miR-200b by cancer-associated fibroblasts contribute to cancer invasion and peritoneal dissemination in gastric cancer. Carcinogenesis. (2015) 36:133–41. doi: 10.1093/carcin/bpu232
14. Wang XZ, Hang YK, Liu JB, Hou YQ, Wang N, Wang MJ. Over-expression of microRNA-375 inhibits papillary thyroid carcinoma cell proliferation and induces cell apoptosis by targeting eRBB2. J Pharma Sci. (2016) 130:78–84. doi: 10.1016/j.jphs.2015.12.001
15. Chow CK, Liu RT, Kang HY. MicroRNA-146b: a Novel biomarker and therapeutic target for human papillary thyroid cancer. Int J Mol Sci. (2017) 18:636. doi: 10.3390/ijms18030636
16. Dai L, Wang Y, Chen L, Zheng J, Li J, Wu X. MiR-221, a potential prognostic biomarker for recurrence in papillary thyroid cancer. World J Surg Oncol. (2017) 15:11. doi: 10.1186/s12957-016-1086-y
17. Xiong Y, Kotian S, Zeiger MA, Zhang L, Kebebew E. miR-126-3p inhibits thyroid cancer cell growth and metastasis, and is associated with aggressive thyroid cancer. PLoS ONE. (2015) 10:e0130496. doi: 10.1371/journal.pone.0130496
18. Lee JC, Zhao JT, Clifton-Bligh RJ, Gill A, Gundara JS, Ip JC, et al. MiRNA-222 and microRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer. Cancer. (2013) 119:4358–65. doi: 10.1002/cncr.28254
19. Gao Q, Zheng J. microRNA-323 upregulation promotes prostate cancer growth and docetaxel resistance by repressing p73. Biomed Pharma. (2018) 98:528–34. doi: 10.1016/j.biopha.2017.10.040
20. Wang C, Liu P, Wu H, Cui P, Li Y, Liu Y, et al. MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of sMAD2 and sMAD3. Oncotarget. (2016) 7:14912–24. doi: 10.18632/oncotarget.7482
21. Yoon JH, Lee HS, Kim EK, Moon HJ, Kwak JY. Thyroid nodules: nondiagnostic cytologic results according to thyroid imaging reporting and data system before and after application of the bethesda system. Radiology. (2015) 276:579–87. doi: 10.1148/radiol.15142308
22. Moon HJ, Kim EK, Yoon JH, Kwak JY. Malignancy risk stratification in thyroid nodules with nondiagnostic results at cytologic examination: combination of thyroid imaging reporting and data system and the bethesda system. Radiology. (2015) 274:287–95. doi: 10.1148/radiol.14140359
23. Zhang J, Liu BJ, Xu HX, Xu JM, Zhang YF, Liu C, et al. Prospective validation of an ultrasound-based thyroid imaging reporting and data system (TI-RADS) on 3980 thyroid nodules. Int J Clin Exp Med. (2015) 8:5911–7.
24. Rodolico V, Cabibi D, Pizzolanti G, Richiuse P, Gebbia N, Martorana A, et al. BRAF v600E mutation and p27kip1 expression in papillary carcinomas of the thyroid. <0.01 cm and their paired lymph node metastases. Cancer. (2007) 110:1218–26. doi: 10.1002/cncr.22912
25. Pesutic-Pisac V, Punda A, Gluncic I, Bedekovic V, Pranic-Kragic A, Kunac N. Cyclin d1 and p27 expression as prognostic factor in papillary carcinoma of thyroid: association with clinicopathological parameters. Croatian Med J. (2008) 49:643–9. doi: 10.3325/cmj.2008.5.643
26. Liu C, Su C, Chen Y, Li G. MiR-144-3p promotes the tumor growth and metastasis of papillary thyroid carcinoma by targeting paired box gene 8. Cancer Cell Int. (2018) 18:54. doi: 10.1186/s12935-018-0550-y
27. Ma S, Jia W, Niu S. miR-199a-3p inhibits the progression of papillary thyroid carcinoma by targeting sNAI1. Biochem Biophys Res Commun. (2018) 497:181–6. doi: 10.1016/j.bbrc.2018.02.051
28. Kotlarek M, Kubiak A, Czetwertynska M, Swierniak M, Gierlikowski W, Kolanowska M, et al. The rs2910614 genetic variant of miR-146a-3p is associated with increased overall mortality in patients with

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2020.00122/full#supplementary-material

Supplementary Table 1 | Clinical features, including gender, tumor size, capsular invasion, lymph node metastasis, number of cancer foci, and BRAF mutation, were presented in healthy controls and PTC and BPN patients.
fOLLICULAR VARIANT PAPILLARY THYROID CARCINOMA. Int J Mol Sci. (2018) 19:655. doi: 10.3390/ijms19030655
29. Mian C, Pennelli G, Fassan M, Balistreri M, Barollo S, Cavedon E, et al. MicroRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with RET status and outcome. Thyroid. (2012) 22:890–6. doi: 10.1089/thy.2012.0045
30. Cahill S, Smyth P, Denning K, Flavin R, Li I, Potratz A, et al. Effect of bRafV600E mutation on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model. Mol Cancer. (2007) 6:21. doi: 10.1186/1476-4598-6-21
31. Al-Dhahiry JK, Hameed HM. Total thyroidectomy: conventional suture ligation technique versus sutureless techniques using harmonic scalpel or maximal. Ann Med Surg. (2016) 5:29–34. doi: 10.1016/j.amsu.2015.11.010
32. Nguyen QT, Lee EI, Huang MG, Park YI, Khullar A, Ploibilities RA. Diagnosis and treatment of patients with thyroid cancer. American Health Drug Benefits. (2015) 8:30–40.
33. Baldini E, Sorrenti S, Tuccilli C, Prinzi N, Coccaro C, Catania A, et al. Emerging molecular markers for the prognosis of differentiated thyroid cancer patients. Int J Surg. (2014) 1:552–6. doi: 10.1016/j.ijsu.2014.05.054
34. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Institute. (2003) 95:625–7. doi: 10.1093/jnci/95.8.625
35. Kimura ET, Nikiforova MN, Zhu Z, Knauf IA, Nikiforov YE, Fagin JA. High prevalence of bRaf mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. (2003) 63:1454–7.
36. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. (2002) 417:949–54. doi: 10.1038/nature00766
37. Millington GW. Mutations of the BRAF gene in human cancer, by Davies et al. (Nature 2002 417: 949-54). Clin Exp Derm. (2013) 38:222–3. doi: 10.1111/ced.12015
38. Li QK, Nugent SL, Straseski J, Cooper D, Riedel S, Askin FB, et al. Thyroglobulin measurements in fine-needle aspiration cytology of lymph nodes for the detection of metastatic papillary thyroid carcinoma. Cancer Cytopathol. (2013) 121:440–8. doi: 10.1002/cncy.21285
39. Hanna AN, Michael CW, Jing X. Mixed medullary-follicular carcinoma of the thyroid: diagnostic dilemmas in fine-needle aspiration cytology. Diag Cytopathol. (2011) 39:862–5. doi: 10.1002/dc.21560
40. Frasoldati A, Valcavi R. Challenges in neck ultrasonography: lymphadenopathy and parathyroid glands. Endocrine Pract. (2004) 10:261–8. doi: 10.4158/EP.10.3.261
41. Wang T, Liu Y, Lv M, Xing Q, Zhang Z, He X, et al. miR-323-3p regulates the steroidogenesis and cell apoptosis in polycystic ovary syndrome (PCOS) by targeting IGF-1. Gene. (2019) 683:87–100. doi: 10.1016/j.gene.2018.10.006
42. Zhang H, Wang X, Chen X. Potential role of long non-Coding RNA aNRIL in pediatric medulloblastoma through promotion on proliferation and migration by targeting miR-323. J Cell Biochem. (2017) 118:4735–44. doi: 10.1002/jcb.26141
43. Fan JM, Zheng ZR, Zeng YM, Chen XY. MiR-323-3p targeting transmembrane protein with eGF-Like and 2 follistatin domain (TMEFF2) inhibits human lung cancer a549 cell apoptosis by regulation of aKT and eRK signaling pathways. Med Sci Monitor. (2020) 26:e919454. doi: 10.12659/MSM.919454

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Liu, Li, Liu, Yuan and Lu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.